MSF rolls out Hepatitis C test and treat campaign in Rohingya Camps, Bangladesh

 To address concerningly high levels of hepatitis C in the Rohingya refugee camps in Cox's Bazar, Bangladesh, 30,000 people will receive care by the end of 2026 as Médecins Sans Frontières (MSF) significantly expands its treatment programmes.

The initiative improves access to hepatitis C care for a group of stateless people who are particularly exposed to this curable but potentially fatal disease. MSF is establishing three specialised hepatitis C treatment centres within existing health facilities inside the camps as part of a "test and treat" campaign covering an estimated third of all people living with hepatitis C in the camps. 

Between October 2020 and December 2024, MSF treated over 10,000 people for hepatitis C at our clinics in the camps in Jamtoli and Hospital on the Hill. However, a 2023 MSF study published last month in The Lancet Gastroenterology & Hepatology found that nearly one in five adults—an estimated 86,000 people—live with chronic active infection, highlighting the urgent need for a more robust response.

"Access to hepatitis C care in the camps, where more than a million refugees have been living for the past eight years, has been minimal," says Dr Wasim Firuz, MSF deputy medical coordinator. "Treating hepatitis C is not part of the healthcare package provided by over-stretched healthcare facilities. People are also not allowed to leave the camps to access healthcare freely, and even if they could, it's unlikely they would be able to afford the cost of treatment."

Harsh living conditions in the cramped and overcrowded camps, a lack of access to or reduced provision of healthcare, and a lack of legal status, which severely restricts their fundamental rights, have made Rohingya refugees more vulnerable to infections, including hepatitis C, in Myanmar and Bangladesh. Our survey found that exposure to unsafe medical practices for decades, such as therapeutic injections, could be the main reason for the transmission of this bloodborne disease within the camps. 

Our scaled-up programme, in response, sees teams conducting systematic community-based screening to identify people with hepatitis C proactively. This disease does not show any signs or symptoms in its first phase. Rapid testing is followed by laboratory confirmation at the newly established treatment centres in Balukhali, Jamtoli, and Hospital on the Hill. We are also implementing a comprehensive healthcare awareness campaign, which includes providing drugs for hepatitis C treatment and sharing prevention messages and treatment adherence counselling to adults. 

"In the absence of other alternatives to hepatitis C care for tens of thousands of people in the camps, we are undertaking this substantial increase in our treatment capacity," says Dr Firuz. "Our goal is to reach 30,000 people with curative care by the end of 2026. This expansion represents a vital step towards preventing the spread of hepatitis C, especially to younger generations." 

Addressing this widespread hepatitis C epidemic nonetheless presents considerable challenges within the limited capacity of the overall health response in the camps. MSF will research to analyse such challenges and propose solutions as part of its response. 
"While we are scaling up efforts and working in coordination with other organisations, the limitations within the health response, including insufficient staffing, equipment, and resources among partners, present a significant obstacle," says Dr Firuz. "Our temporary campaign will not eradicate hepatitis C in the camps. Attention to hepatitis C must continue during and after the end of this campaign. Again, we call on other health partners and the international community to prioritise building a comprehensive strategy to reduce the devastating impact of this disease on this community